Dergiler / Psychiatry and behavioral sciences (Online) / 2018 / Cilt: 8 - Sayı: 3

The Occurrence of Psychotic Manifestation Following the Initiation of Everolimus in a Patient with Tuberous Sclerosis: A Possible Involvement of Dysregulated mTOR Cascade

Sayfa
137–141
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although it would be difficult to allege the direct involvement of short-term everolimus exposure in the development of psychotic symptoms, impaired protein synthesis related to the mTOR inhibition leads to impaired neuronal network and plasticity, and may predispose to the development of psychotic symptoms, consequently.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Tuberous sclerosis (TSc) is an autosomal dominant multisystemic disorder.
📊
Temel Bulgular & Veri:Mutant TSC1 and TSC2 are the responsible genes for the disorder that leading to a hyperactivation of the mammalian target of rapamycin (mTOR), a signaling cascade involved in cell growth, proliferation, protein synthesis, and metabolism.
💡
Sonuç & Katkı:Although it would be difficult to allege the direct involvement of short-term everolimus exposure in the development of psychotic symptoms, impaired protein synthesis related to the mTOR inhibition leads to impaired neuronal network and plasticity, and may predispose to the development of psychotic symptoms, consequently.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Tuberous sclerosis (TSc) is an autosomal dominant multisystemic disorder. Mutant TSC1 and TSC2 are the responsible genes for the disorder that leading to a hyperactivation of the mammalian target of rapamycin (mTOR), a signaling cascade involved in cell growth, proliferation, protein synthesis, and metabolism. Everolimus and sirolimus, the mTOR inhibitors, are recently offered to restore pathologically up-regulated mTOR pathway in TSc. However, the neuropsychiatric side effects of these drugs are yet to be studied. Here we reported a 22-year-old male patient, with diagnoses of tuberous sclerosis, epilepsy, learning disability, and organic personality disorder without any psychotic manifestations, who was admitted to our outpatient clinic because of disorganized behavior, hallucinations, and delusions with a recent history of hostility and aggression. The aforementioned psychotic manifestations initiated soon after he had undergone on a placebo-controlled double-blind study of everolimus 6 mg/daily for TSc for last four months. Clinical examination, laboratory screening, and magnetic resonance imaging (MRI) of the brain have not revealed any other organic causes of psychosis. His symptoms resolved over the next ten or so days with moderate doses of antipsychotics. The current case is presented in order to discuss possible underlying neuronal signaling mechanisms those may lead psychosis following a short-term mTOR inhibition treatment. Although it would be difficult to allege the direct involvement of short-term everolimus exposure in the development of psychotic symptoms, impaired protein synthesis related to the mTOR inhibition leads to impaired neuronal network and plasticity, and may predispose to the development of psychotic symptoms, consequently.

🔖

Bu Makaleye Atıf Yap

ŞENAY, O., BALCIOĞLU, Y. H., İLNEM, M. C. (2018). The Occurrence of Psychotic Manifestation Following the Initiation of Everolimus in a Patient with Tuberous Sclerosis: A Possible Involvement of Dysregulated mTOR Cascade. Psychiatry and behavioral sciences (Online), Cilt: 8 - Sayı: 3, 137–141. https://ajindex.com/articles/302864

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008
  2. 372(9639):657-68. [CrossRef] 2. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015
  3. 14(7):733-45. [CrossRef] 3. Leclezio L, de Vries PJ. Advances in the treatment of tuberous sclerosis complex. Curr Opin Psychiatry 2015
  4. 28(2):113-20. [CrossRef] 4. Tasdemir A, Kalelioglu T, Genc A, Kalelioglu T, Umut G. Psychosis in a female patient with tuberous sclerosis. J Neuropsychiatry Clin Neurosci 2013
  5. 25(2):E61. [CrossRef] 5. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: the Turkish version of Naranjo adverse drug reactions probability scale. Psychiatry and Clinical Psychopharmacology 2017
  6. 27(2):205-6. [CrossRef] 6. Kitagishi Y, Kobayashi M, Kikuta K, Matsuda S. Roles of PI3K/ AKT/GSK3/mTOR pathway in cell signaling of mental illnesses. Depress Res Treat 2012
  7. 752563. 7. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1 alpha transcriptional complex. Nature 2007
  8. 450(7170):736-40. [CrossRef] 8. Aiello R, Crupi R, Leo A, Chimirri S, Rispoli V, Marra R, et al. Long-term betamethasone 21-phosphate disodium treatment has distinct effects in CD1 and DBA/2 mice on animal behavior accompanied by opposite effects on neurogenesis. Behav Brain Res 2015
  9. [CrossRef] 9. Bösche K, Weissenborn K, Christians U, Witzke O, Engler H, Schedlowski M, Hadamitzky M. Neurobehavioral consequences of small molecule-drug immunosuppression. Neuropharmacology 2015
  10. 96(PA):83-93. 10. Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and noncognitive components of behavior throughout lifespan in mice. Neuroscience 2012
  11. [CrossRef] 11. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012
  12. 37(1):4-15. [CrossRef] 12. Gong R, Park CS, Abbassi NR, Tang SJ. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem 2006
  13. 281(27):18802-15. [CrossRef] 13. Gururajan A, van den buuse M. Is the mTOR-signalling cascade disrupted in Schizophrenia? J Neurochem. 2014 May
  14. 129(3):377-87. [CrossRef] 14. Zho